Phase II study of multi-agent chemotherapy in patients with adult Burkitt leukemia.

Phase II study of multi-agent chemotherapy in patients with adult Burkitt leukemia. - Study of multi-agent chemotherapy in patients with adult Burkitt leukemia. (JALSG Burkitt-ALL213)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010641

Enrollment

Registered

2013-05-15

Start date

2013-07-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burkitt leukemia

Interventions

Rituximab combined chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Recognized ALL 2. Burkitt-ALL (diagnosed by WHO Classification) 3. Age 15 to 64 4. Performance Status: 0 to 3 5. Adequate hepatic, renal and cardiac function 6. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Previously treated with leukapheresis 2. Congestive heart failure 3. Recent history of myocardial infarction 4. Malignant hypertension 5. Lung fibrosis 6. Interstitial pneumonitis 7. Severe comorbidity (diabetes mellitus, infection or liver cirrhosis) 8. Positive anti-HIV antibody or HBs antigen 9. Thrombosis which need treatment 10. Psychological disorders 11. Other active neoplasms 12. Pregnant and/or lactating woman 13. Judged to be inadequate

Design outcomes

Primary

Measure	Time frame
3 year event free survival (EFS)	—

Secondary

Measure	Time frame
Complete remission rate Adverse event rate 3 year overall survival (OS), and disease free survival (DFS)	—

Countries

Japan

Contacts

Public ContactTohru Murayama

JALSG-ALL-213 research secretariat Hyogo Cancer Center, Department of Hematology

tmurayam@hp.pref.hyogo.jp078-929-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026